Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand
March 9, 2021
Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offering Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments. Cybin appears set for rapid growth as research accelerates, public acceptance grows. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and […]
InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters Strategic LOI with ShroomBloom
March 9, 2021
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced that it signed a letter of intent (“LOI”) with ShroomBloom Labs/Floja Bioscience Inc. to enter into an agreement for the supply of psychedelic mushroom biomass. British Columbia-based ShroomBloom […]
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Inks First CBD Oil Commercial Sale; Looks to Grow in Key Spaces
February 25, 2021
Pure Extracts is preparing to deliver shipment of 85% pure CBD distillate Company proud of quality offering produced in world-class facility PULL uses proprietary state-of-the art, sub-critical/super-critical CO2extraction system Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has signed a contract for its first CBD oil commercial sale on the wholesale market (https://ibn.fm/92kPG). […]
InvestorNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) to File Restated Financial Statements, MD&A
February 18, 2021
Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) has announced that, after review, it will refile its condensed interim consolidated financial statements and management’s discussion & analysis (“MD&A”) for the three- and six-month periods ended March 31, 2020. In earlier versions of the MD&A, Champignon had recognized intangible assets that had resulted from the acquisitions of Artisan […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Outlines 2021 Business Strategies for COVID-19 PCR Testing and Psychedelic Treatments
February 16, 2021
XPhyto Therapeutics Corp. plans to commercialize its rapid and portable PCR Kit this year to provide point-of-care diagnostics The company is confident about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021 Hugh Rogers, CEO and Director of XPhyto, revealed in the latest news release that the company […]
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Delineates Parameters and Timeline of Study into Psilocybin-Based Active Treatments
February 16, 2021
Pure Extract Technologies pursues study into psilocybin active treatments Study to extend for 250-day period, targeting a number of milestones The study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor Oregon recently voted to legalize psilocybin mushrooms for therapeutic use, […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Studying Potential for Psychedelics in Treatment of Mental Health Conditions, Announces Addition of Mescaline to Subsidiary Medicine Programs
February 10, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is involved in preclinical laboratory work designed to study a variety of psychotropic compounds, including psilocybin, mescaline, LSD, MDMA and DMT. The company also announced that its subsidiary, XPhyto Laboratories Inc., has added the production of mescaline […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin
February 5, 2021
Cybin (NEO: CYBN) is a mushroom life science company focused on the pharmaceutical development of psychedelic products. Cybin’s subsidiary Serenity Life Sciences is engaged in the research and development of psilocybin-based medications. Widely referred to as magic mushrooms, Psilocybin has had its share of bad press. However, the company is positioned as perceptions of this […]
InvestorNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Board Changes
February 4, 2021
Champignon Brands’ (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Chairman, Dr. Roger McIntyre, today announced changes to its board of directors. According to the update, Bill Wilkerson, LL. D. (Hon), appointed to the company’s board of directors on May 22, 2020, and elected its vice-chair on Sept. 14, 2020, after completing his six-month commitment, has retired […]
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Updates Investors Following Completion of Special Warrants Private Placement
February 3, 2021
Pure Extracts recently updated investors on successful completion of second tranche of its special warrants private placement In aggregate, Company will raise gross proceeds of $8.5 million through both tranches of private placement Pure Extracts will employ net proceeds from private placement towards capacity expansion for Company’s extraction business, and for general working capital purposes […]
InvestorNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Publication of Article Led by CEO Dr. Roger McIntyre
February 3, 2021
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) today announced the publication of an article led by its CEO Dr. Roger McIntyre. The article, titled, “The Rapid Mood Screener (‘RMS’): a novel and pragmatic screener for bipolar I disorder,” is published at Taylor and Francis.com. “Timely and accurate diagnoses are precursors of good clinical outcomes […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Signs Production Agreement with Applied Pharmaceutical Innovation
February 3, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has signed an agreement with Applied Pharmaceutical Innovation. A not-for-profit institution at the University of Alberta, Applied supports translational drug development for industry and innovators. XPhyto’s psychedelic pharmaceutical production agreement calls for the synthesis […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Is ‘One to Watch’
February 2, 2021
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities The company has research and development operations in North America and Europe and an operational focus in Germany XPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD
January 29, 2021
Cybin (NEO: CYBN), a mushroom life science company, is at the forefront of new treatments targeting major depressive disorder (“MDD”). The company is working to become the first to bring a psilocybin drug to market that targets MDD. This positions Cybin to provide solutions amid significant demand, with more than 18 million people in the […]
InvestorNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Opens New CRTCE Clinic to Provide Ketamine Treatment for Adults with Depression
January 25, 2021
Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions, has opened its third Canadian Rapid Treatment Center of Excellence (“CRTCE”) clinic. Champignon chairman and CEO Roger McIntyre announced the opening of the center; the announcement noted that the clinics — the […]
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Commences Research into Psilocybin-Based Active Treatments
January 20, 2021
Pure Extracts commences study into psilocybin-based active treatments Study set to be carried out at Toronto Institute of Pharmaceutical Technology, supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor Study will delve into carrying out conformity testing, stability testing for psilocybin products thereby commencing the R&D that will ultimately take place at Pure Extracts’ purpose-built […]
InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Announces Upcoming Study on Psilocybin-Based Nasal Gel, Oral Tablets and Capsules
January 14, 2021
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has released the timetable and milestones for a proprietary study. The study is designed to evaluate the formulation, manufacturing and clinical bioavailability of psilocybin-based, rapid-onset active treatments for a nasal gel as well as oral tablets and […]
InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Leverages Key Experience, Prepares Entry into Psychedelic Mushroom Market
January 12, 2021
Pure Extracts (CSE: PULL), a plant-based extraction company, is focused on cannabis, hemp, and functional mushroom sectors, the last of which is projected to rise to a value of $34.4 billion by the end of 2024. Seeking to capitalize on the growing interest within the sector, Pure Extracts has expanded its business model to include […]
Health Canada Grants Selected Physicians Access to Psilocybin Mushrooms as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Dives into Functional Mushroom Market
January 12, 2021
Health Canada recently granted psilocybin testing access to selected physicians Psilocybin mushrooms shown to help patients suffering from addiction, mental health issues Pure Extracts’ ’Pure Mushrooms’ and ‘Pure Pulls’ branded products expected to be available by end of Q1 2021 In a recent virtual townhall, Canadian Health Minister Patty Hajdu disclosed that the Canadian government […]
InvestorNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces New CFO, General Counsel
January 11, 2021
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) chairman and CEO Roger McIntyre today announced the company’s appointment of Stephen R. Brooks as its new chief financial officer and Peter Rizakos as the firm’s new general counsel. According to the update, these appointments complete the company’s new top management team put into place by Dr. McIntyre […]
InvestorNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Article Outlining Future Potential in Novel Agents for Bipolar Disorders
January 8, 2021
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) today announced the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article, “Bipolar Disorders” is published in The Lancet – one of the world’s best-known and most reputable scientific journals in medicine. According to the update, the article contributes to The […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) Releases Report on Patent Filings, Therapeutics Program Development
January 6, 2021
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, has provided an update on its patent filings. The company has eight filings, all tied to Cybin’s novel therapeutics, delivery mechanisms and treatment regiments. The patent updates noted that Cybin has patent applications for the following: a provisional patent application for an oral […]
Pure Extracts Technologies (CSE: PULL) Draws Out Expansion Plans in Anticipation of Regulatory Changes Within Mushroom Sector
January 6, 2021
Pure Extracts Technologies Corp. has announced plans to expand, build fourth unit in dedicated towards research, development of psilocybin Announcement on its expansion plans come shortly after the Company revealed it plans to apply to Health Canada for a Dealer’s License Award of Dealer’s License would allow Pure Extracts to cultivate, harvest and procure controlled […]
Cybin Inc. (NEO: CYBN) R&D Sees Hope in Growing Acceptance of Psilocybin
January 5, 2021
U.S. taking actionable steps toward acceptance of psilocybin States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority More psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of […]
Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy
December 31, 2020
Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD Newly discoverable data from psychedelic studies may potentially create entirely new marketplace of safe and effective drugs Cybin (NEO: CYBN), a mushroom life sciences company, […]
InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Commences Study to Further Knowledge in Psilocybin, Associated Delivery Mechanisms
December 30, 2020
Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushrooms sector, today announced that it is commencing a study on the formulation and manufacturing of psilocybin-based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) on Track to Leverage Psychedelics to Target Depression
December 28, 2020
Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry,” only two doses of psilocybin accompanied with psychotherapy may lead […]
Pure Extracts Technologies (CSE: PULL) Signs LOI with PURICA(TM) to Further Research into Mushrooms Wellness Products
December 23, 2020
Pure Extracts Technologies revealed it had recently retained global consultancy to advise on application for Dealer’s License under Health Canada If granted, license would allow Company to cultivate, conduct research into, commercialize controlled substances Pure Extracts also announced it recently signed LOI to further cooperation with PURICA(TM)( in field of full-spectrum mushroom-derived wellness products and […]
Pure Extracts Technologies Corp. (CSE: PULL) Names Key Advisor; Targets Development of Mushroom Formulations
December 21, 2020
Pure Extracts is working with Dr. Alexander MacGregor on development of mushroom products, including some combined with CBD. MacGregor is widely renowned as pharmaceutical science inventor, expert in pharmaceutical technology and novel drug-delivery systems. Pure Extracts is focused on expansion of its cannabis extraction business model to include mushroom formulations. Pure Extracts Technologies (CSE: PULL) […]
InvestorNewsBreaks – Loop Insights Inc. (TSXV: MTRX) (OTCQB: RACMF) Announces Launch of Digital Connect Health Platform
December 21, 2020
Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced the January 2021 launch of its Digital Connect Health Platform, a fully-integrated digital health care solution designed for both government and private sector. […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Marks Significant Milestone with Commencement of CSE Trading
December 18, 2020
Tryp Therapeutics (CSE: TRYP) today announced that its common shares have commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “TRYP” effective Dec. 18, 2020. “Trading on the CSE is a significant milestone in Tryp’s mission to transform the treatment of neuropsychiatric diseases with safe and effective psychedelic medicines,” said Tryp CEO James […]
Cybin Inc. (NEO: CYBN) Looking to Solve Long-Standing Problem with MDD Treatment
December 18, 2020
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) — NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Hope on the Horizon: Psychedelics Offer Potential for Transforming Mental Health Treatments.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/RTJ3w More than 700 million people dealing with illnesses takes […]
Pure Extract Technologies (CSE: PULL) Provides Update on Expansion into Functional Mushrooms Sector
December 17, 2020
Pure Extracts Technologies recently provided update into its expansion into functional mushrooms sector Functional mushrooms have enjoyed surge in popularity as of late, are increasingly being used in wide variety of healthcare, pharmaceutical products Functional mushrooms sector is expected to grow to annual market value of $34.4 billion by 2024 Pure Extracts plans to develop […]
Cybin Inc. (NEO: CYBN) Acquisition, Three-Pillar Approach Reason for Optimistic MDD Outlook
December 17, 2020
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) — via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Hope on the Horizon: Psychedelics Offer Potential for Transforming Mental Health […]
InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Begins Facility Build-Out, Prepares to Apply for Dealer’s Licence
December 16, 2020
Pure Extracts Technologies (CSE: PULL), a plant-based extraction company, has begun build-out work on the fourth unit in is extraction facility; in addition, the company is preparing to submit application to Health Canada requesting a dealer’s licence under the Controlled Drugs and Substances Act (“CDSA”), the government entity that provides the framework for legal access […]
InvestorNewsBreaks – Way2Grow (‘W2G’) Biopharma Company Announces Entry into Cannabis Productivity, Plans for Psychedelic Research and Development
December 15, 2020
Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately held biopharma company, today announced its entry into the productivity phase of cannabis cultivation, micropropagation and extraction. The company also announced its preparation of a Health Canada application towards psychedelic research and development for a medicinal mushroom (Psilocybe semilanceata) Dealer Licence and a Section 56 Exemption for use […]
Cybin Inc. (NEO: CYBN) on Right Path; Johns Hopkins Study Shows Psilocybin Positive Impact on Major Depression
December 15, 2020
Study published in “JAMA Psychiatry” reveals significant benefits of psilocybin for patients with major depression Most participants reported improvements; half experienced remission after only four weeks As an early entrant in the field, Cybin looks well placed to capitalize on growing traction that psychedelics gain as potential treatment of mental health conditions Only two doses […]
InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Notes Appreciation for Health Canada Milestone Special Access Programme
December 15, 2020
Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, has voiced its support and appreciation for Health Canada’s recently announced Special Access Programme (“SAP”) for psilocybin-assisted psychotherapy inclusion. The government entity recently announced its intent to revise the SAP and other related regulations to […]
Way2Grow (W2G) Biopharma Company Enters Cannabis Productivity and Announces Plans to Seek Health Canada Approval for Magic Mushroom (Psilocybin and Psilocin) Dealer and Research Licencing
December 15, 2020
OSOYOOS, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) — via CannabisNewsWire – Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately held biopharma company, is pleased to announce it is entering the productivity phase of cannabis cultivation, micropropagation and extraction. The company further announces its preparation of a Health Canada application towards psychedelic research and development for […]
Mind Medicine Inc. (MMEDF) Featured in Virtual Coverage of Benzinga’s Global Small Cap Conference
December 9, 2020
Mind Medicine Inc. (OTCQB: MMEDF) is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed […]